Matinas BioPharma Announces Chairman Succession Plan
BEDMINSTER, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform delivery technology, today announced its leadership succession plan, with the Board of Directors unanimously appointing current board member, Eric J. Ende, to succeed Herbert J. Conrad as Chairman of the Board. Mr. Conrad, the founding Chairman of Matinas will remain on the Board as an independent director of the Company. The succession will be effective October 1, 2022.
Related news for (MTNB)
- Today’s Top Performers: MoBot’s Market Review 08/15/25 01:00 PM
- Breaking News: MoBot’s Latest Update as of 08/15/25 12:00 PM
- Six Exciting Materials Stocks Heating Up the Market
- 111 Equity Group increases stake in Matinas Biopharma Holdings, Inc.
- Matinas BioPharma Announces that MAT2203 Will Be Featured in Two Oral Presentations at ECCMID